Biogen BIIB Alzheimer's collaboration revenue — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biogen's alzheimer's collaboration revenue — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's alzheimer's collaboration revenue — total revenue?
- Biogen (BIIB) reported alzheimer's collaboration revenue — total revenue of $59.5M in Q1 2026.
- How has Biogen's alzheimer's collaboration revenue — total revenue changed year-over-year?
- Biogen's alzheimer's collaboration revenue — total revenue increased by 80.3% year-over-year, from $33M to $59.5M.
- What does alzheimer's collaboration revenue — total revenue mean?
- This metric represents the total gross revenue recognized by the company from collaborative arrangements specifically focused on the development and commercialization of Alzheimer's disease therapeutics. It captures the company's share of product sales and related milestone payments generated through joint ventures or strategic partnerships with other pharmaceutical entities. This figure serves as a primary indicator of the commercial traction and market adoption of the company's novel neurodegenerative disease portfolio.